Cardioprotection on Chemotherapy-Induced Cardiotoxicity

Launched by AIN SHAMS UNIVERSITY · Feb 25, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how certain medications can protect the heart from damage caused by chemotherapy. Chemotherapy can sometimes lead to a condition called cardiotoxicity, which harms the heart. The researchers are looking for ways to reduce this risk and keep patients’ hearts healthy while they undergo cancer treatment.

The trial is open to children and teenagers aged 2 to 18 years who are willing to participate. To join, a parent or guardian must agree to the study, and the young participants should be able to take oral medications. However, anyone who has an allergy to the cardioprotective medications cannot participate. If eligible, participants will receive the cardioprotective medications during their chemotherapy treatments and will be monitored for their heart health. This study aims to ensure that young cancer patients can receive the best possible care with minimal side effects on their hearts.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Willingness of the legal representative of research participant to participate in the study by giving "informed consent."
• • Ability to take oral medication.
• • Age 2-18 years at the time of diagnosis.
• Exclusion Criteria:
• • Documented allergy to cardioprotective medications